Clinical trial · people

Setmelanotide: mean BMI fell 18% at 52 weeks in ages 2-5 (VENTURE)

Checked against the paper Clinical trialPublished by PepVault

The takeaway

This is the first trial of setmelanotide in children under 6, and it found BMI drops and less hunger in this small group, with larger drops in POMC or LEPR deficiency than in BBS.

Kind
Clinical trial
Studied in
People
Number studied
12
Published
2025
Journal
Lancet Diabetes Endocrinol

What they tested

The team tested whether daily setmelanotide shots work and are safe in very young children, aged 2-5, with obesity and extreme hunger caused by POMC or LEPR deficiency or Bardet-Biedl syndrome (BBS).

How the study was done

An open-label phase 3 trial, with no comparison group, at six sites in the USA, the UK, Spain, and Australia. It enrolled 12 children aged 2-5 (seven with POMC or LEPR deficiency, five with BBS), who took setmelanotide under the skin once a day for 52 weeks, with the dose stepped up every 2 weeks.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

PepVault for iPhone

Taking setmelanotide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

At week 52, 10 (83%) of the 12 children had a drop of 0.2 points or more in BMI Z score, a score that compares a child's BMI with others of the same age and sex. On average, BMI changed by -18% (SD 13) overall: -26% (SD 11) in children with POMC or LEPR deficiency and -10% (SD 9) in children with BBS. Of caregivers, 91% said the child was less hungry than at the start. All side effects were mild or moderate, most often skin darkening, vomiting, colds, upper airway infections, and injection site reactions, and there were no serious side effects.

What it doesn’t show

This was a small, 1-year trial with no placebo or comparison group, and everyone knew they were getting the drug. It only included children with these specific genetic conditions, and it was funded by Rhythm Pharmaceuticals.

The paper

Argente et al. Setmelanotide in patients aged 2-5 years with rare MC4R pathway-associated obesity (VENTURE): a 1 year, open-label, multicenter, phase 3 trial. Lancet Diabetes Endocrinol. 2025.

The compound

More studies on Setmelanotide

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking setmelanotide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo